Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company, has focused their efforts on the development of pharmaceutical product candidates designed to treat obesity and other central nervous system-related disorders. The company’s lead combination product candidates targeted for obesity include: Contrave®, which is in Phase 3 clinical trials; and Empatic™, which is in the later stages of Phase 2 clinical development. For further information, visit the Company’s web site at www.orexigen.com.
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
November 3, 2008 at 4:39am
Archives
Select A Month
